Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease‎

Anavex Announces CTAD 2015 Abstract

Anavex Commences Trading on NASDAQ Today – To Ring Friday’s Closing Bell

Anavex Announces Uplisting to NASDAQ

Anavex to Present at 4th Annual OktoberINVESTfest Conference

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference

Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split

Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule

Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference

Anavex Appoints International Alzheimer’s Expert to Scientific Advisory Board